Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO
Observational studyHumansWith a patented fatty acid mixture (OnLife)
This study tested palmitoylethanolamide together with a patented fatty acid mixture (OnLife). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Observational study
- Subjects
- 146 patients in Germany with neuropathy after paclitaxel (75 breast cancer) or oxaliplatin (71 colon cancer)
- Dose used in the study
- OnLife, a supplement of specific fatty acids with palmitoylethanolamide; dose not in the abstract
- Duration
- 3 months after the end of chemotherapy
- What was measured
- Clinician-graded sensory and motor neuropathy before and after treatment; patient-reported quality of life and symptoms
What the authors reported
Sensory neuropathy improved in 31 percent of breast cancer patients and 17 percent of colon cancer patients; motor neuropathy in 38 and 20 percent. Patient-reported symptom reduction occurred in 46 percent (paclitaxel) and 24 percent (oxaliplatin) of patients.
Limits of this study
No control group. Chemotherapy neuropathy often improves in the months after treatment stops, which is exactly the period studied. Several authors report industry honoraria; the study was of a commercial product. A multi-ingredient product.
Source
PubMed 34496363 · doi:10.1159/000519000
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.